TGF-β stimulates biglycan core protein synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation in vascular smooth muscle

Growth Factors

Volumn 29, Issue 5, 2011, Pages 203-210

  Osman, Narin ^a   Getachew, Robel ^a   Burch, Micah ^a,b   Lancaster, Graeme ^b   Wang, Rikang ^c   Wang, Haitau ^c   Zheng, Wenhua ^c   Little, Peter J ^a  

^a RMIT UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Akt; Atherosclerosis; Biglycan; Transforming growth factor

Indexed keywords

BIGLYCAN; GLYCOSAMINOGLYCAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEOGLYCAN; SMAD2 PROTEIN; SN 30978; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

BIGLYCAN; CELLS, CULTURED; GLYCOSAMINOGLYCANS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 80052882298     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.615747     Document Type: Article

References (49)

1. Alessi DR, Andjelkovic M, Caudwell B, et al. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551. (Pubitemid 26413787)
2. Bobik A. 2006. Transforming growth factor-βetas and vascular disorders. Arterioscler Thromb Vasc Biol 26:1712-1720. (Pubitemid 44305323)
3. Brunet A, Bonni A, Zigmond MJ, et al. 1999. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868. (Pubitemid 29165088)
4. Burch ML, Yang SN, Ballinger ML, Getachew R, Osman N, Little PJ. 2010a. BRI-βeta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. Cell Mol Life Sci 67:2077-2090.
5. Burch ML, Ballinger ML, Yang SN, et al. 2010b. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor. J Biol Chem 285:26798-26805.
6. Burgering BM, Coffer PJ. 1995. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599-602.
7. Cardone MH, Roy N, Stennicke HR, et al. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321. (Pubitemid 28524494)
8. Cartel NJ, Wang J, Post M. 2002. Platelet-derived growth factor-βB-mediated glycosaminoglycan synthesis is transduced through Akt. Biochem J 363:19-28. (Pubitemid 34280607)
9. Carter AM, Grant PJ. 1997. Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 14:423-432. (Pubitemid 27286512)
10. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789. (Pubitemid 26004411)
11. Dadlani H, Ballinger ML, Osman N, Getachew R, Little PJ. 2008. Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle. J Biol Chem 283: 7844-7852.
12. Das L, Levine AD. 2008. BRI-βeta inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the presence of sustained TCR signal transduction. J Immunol 180:1490-1498.
13. DeFeo-Jones D, Barnett SF, Fu S, et al. 2005. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4:271-279. (Pubitemid 40340206)
14. Derynck R, Zhang YE. 2003. Smad-dependent and Smadindependent pathways in BRI-βeta family signalling. Nature 425:577-584. (Pubitemid 37280136)
15. Diehl JA, Cheng M, Roussel MF, Sherr CJ. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499-3511. (Pubitemid 28553242)
16. Franke TF, Yang SI, Chan TO, et al. 1995. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGFactivated phosphatidylinositol 3-kinase. Cell 81:727-736.
17. Franke TF, Kaplan DR, Cantley LC. 1997. PI3K: downstream AKTion blocks apoptosis. Cell 88:435-437. (Pubitemid 27154408)
18. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. 2000. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/ AKT pathway. J Biol Chem 275:39223-39230. (Pubitemid 32058940)
19. Getachew R, Ballinger ML, Burch ML, et al. 2010. Platelet-derived growth factor {beta}-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to low-density lipoprotein. Endocrinology 151: 4356-4367.
20. Hajduch E, Litherland GJ, Hundal HS. 2001. Protein kinase B (PKB/Akt)-a key regulator of glucose transport? FEBS Lett 492:199-203. (Pubitemid 32217828)
21. Hamamura K, Zhang P, Yokota H. 2008. IGF2-driven PI3 kinase and BRI-β signaling pathways in chondrogenesis. Cell Biol Int 32:1238-1246.
22. Hubchak SC, Sparks EE, Hayashida T, Schnaper HW. 2009. Rac1 promotes BRI-βeta-stimulated mesangial cell type I collagen expression through a PI3K/Akt-dependent mechanism. Am J Physiol Renal Physiol 297:F1316-F1323.
23. Inman GJ, Nicolas FJ, Callahan JF, et al. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-βeta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74. (Pubitemid 34680517)
24. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657. (Pubitemid 34993700)
25. Ismail S, Sturrock A, Wu P, et al. 2009. NOX4 mediates hypoxiainduced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol 296: L489-L499.
26. Lamouille S, Derynck R. 2007. Cell size and invasion in BRI-βetainduced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178:437-451. (Pubitemid 47196152)
27. Little PJ, Tannock L, Olin KL, Chait A, Wight TN. 2002. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-βeta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol 22:55-60. (Pubitemid 34076232)
28. Little PJ, Osman N, O'Brien KD. 2008. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 19:448-454.
29. Li F, Fan C, Cheng T, Jiang C, Zeng B. 2009. Efficient inhibition of fibroblast proliferation and collagen expression by ERK2 siRNAs. Biochem Biophys Res Commun 382:259-263.
30. Liu J, Fitzli D, Liu M, et al. 1998. PDGF-induced glycosaminoglycan synthesis is mediated via phosphatidylinositol 3-kinase. Am J Physiol 274:L702-L713.
31. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151-162. (Pubitemid 34876569)
32. Mori S, Matsuzaki K, Yoshida K, et al. 2004. BRI-βeta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 23:7416-7426.
33. Nakashima Y, Wight TN, Sueishi K. 2008. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res 79:14-23. (Pubitemid 351881944)
34. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. 1999. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344 Pt 2:427-431. (Pubitemid 30011599)
35. --dependent mechanism. Circ Res 67: 814-825. (Pubitemid 20315013)
36. Nigro J, Dilley RJ, Little PJ. 2002. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 162: 119-129. (Pubitemid 34327349)
37. Rahimi RA, Andrianifahanana M, Wilkes MC, et al. 2009. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-βeta. Cancer Res 69:84-93.
38. Runyan CE, Schnaper HW, Poncelet AC. 2004. The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-βeta1. J Biol Chem 279:2632-2639. (Pubitemid 38114250)
39. Schonherr E, Jarvelainen HT, Sandell LJ, Wight TN. 1991. Effects of platelet-derived growth factor and transforming growth factor-βeta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 266:17640-17647. (Pubitemid 21907985)
40. Schonherr E, Jarvelainen HT, Kinsella MG, Sandell LJ, Wight TN. 1993. Platelet-derived growth factor and transforming growth factor-βeta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb 13:1026-1036. (Pubitemid 23195805)
41. Shi Y, Massague J. 2003. Mechanisms of BRI-βeta signaling from cell membrane to the nucleus. Cell 113:685-700. (Pubitemid 36724933)
42. Starkman BG, Cravero JD, Delcarlo M, Loeser RF. 2005. IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK. Biochem J 389:723-729. (Pubitemid 41117332)
43. Tannock L, Little PJ, Wight TN, Chait A. 2002. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res 43:149-157. (Pubitemid 34117229)
44. Voloshenyuk TG, Landesman ES, Khoutorova E, Hart AD, Gardner JD. 2011. Induction of cardiac fibroblast lysyl oxidase by BRI-βeta1 requires PI3K/Akt, Smad3, and MAPK signaling. Cytokine.
45. Wilkes MC, Mitchell H, Penheiter SG, et al. 2005. Transforming growth factor-βeta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 65: 10431-10440. (Pubitemid 41743737)
46. Yang SN, Burch ML, Getachew R, Ballinger ML, Osman N, Little PJ. 2009. Growth factor-mediated hyper-elongation of glycosaminoglycan chains on biglycan requires transcription and translation. Arch Physiol Biochem 115:147-154.
47. Yellaturu CR, Bhanoori M, Neeli I, Rao GN. 2002. N-Ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A. J Biol Chem 277:40148-40155. (Pubitemid 35191007)
48. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. 2001. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3:245-252. (Pubitemid 32201319)
49. Zimmermann S, Moelling K. 1999. Phosphorylation and regulation of Raf by Akt (protein kinase B).Science 286:1741-1744. (Pubitemid 129515882)